Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18-99
SponsorNovartis Pharmaceuticals
About this trial
The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.
Eligibility criteria
Qualifiers
Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of Cycle 1.
≥ 18 years old at the time of enrollment
Written informed consent must be obtained prior to any data collection
Willing to participate in Quality of Life post treatment date collection for 1 year
Disqualifiers
None
Trial design
Treatments tested in this trial
- lutetium (177Lu) vipivotide tetraxetan
Treatment groups
500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov